NBS MAJOR PATENT ALLOWANCE NEWZZZ NeoStem Subsidiary,

New Post Public Reply Private Reply Replies (0) Message Board
Compensated Post
shakerzzz

[b]NBS >> MAJOR PATENT ALLOWANCE NEWZZZ[/b]

NeoStem Subsidiary, Amorcyte, Announces Significant Expansion in Its Claims Granted to Protect the Use of CD34+ Cells

2012-09-10 07:30 ET - News Release


NEW YORK, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Amorcyte, LLC, a subsidiary of NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), today announced a significant expansion in its claims granted to protect the use of CD34+ cells, acquired from blood or bone marrow, to impart a therapeutic benefit to tissue sustaining an ischemic injury. "We received notification that claims granted in the United States have now been granted by the Japanese Patent Office. Additionally, we received recently a Notice of Allowance from the U.S. Patent Office that further expands the scope and protection of our existing CD34+ product patents here in the U.S.," said Andrew Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem. "Collectively, our newly granted and issued claims will support commercialization of AMR-001 globally, if approved, and afford the potential to broaden the scope of AMR-001's development to include repair of ischemic tissue anywhere in the body."

The Japanese Patent Office granted Amorcyte's patent entitled "Compositions and Methods of Vascular Injury Repair." Japan represents another major market to grant patent protection for Amorcyte's product, AMR-001, a CD34+ CXCR4+ cell therapy developed to preserve heart muscle and prevent major adverse cardiac events following acute myocardial infarction (AMI). Related patent applications are being pursued in other global markets. AMR-001 is currently being evaluated in a U.S. Phase 2 clinical trial (PreSERVE AMI) intended to preserve cardiac function and prevent adverse clinical events after a large myocardial infarction.

"The option to pursue our AMR-001 product for the Japanese cardiovascular market with the backing of strong domestic intellectual property protection represents a significant opportunity for NeoStem," said Robin L. Smith, M.D., Chairman and CEO of NeoStem. "Heart disease is the second most prevalent cause of mortality in Japan, according to a meta-analysis published by the American Heart Association. A long-term study (MIYAGI – AMI Registry Study) showed that the incidence of AMI in Japan has significantly increased over the last thirty years, from 7.4 per 100,000 persons/year in 1979 to 27.0 in 2008. Furthermore, Japan's large population of 127 million, together with its wealth (24th out of all nations in terms of per capita GDP), makes it a market that can adopt novel therapeutics like AMR-001 that can potentially extend and improve quality of life as a standard of care."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, as mentioned above, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a robust intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 21

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 0

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 34

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 54

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Duos Technologies Secures $40 Million Offering for Growth

Updated Category News Views 263

Duos Technologies Announces Successful Pricing of Public Offering Duos Technologies Group, Inc. (Nasdaq: DUOT) has successfully priced its public offering of common stock, raising $40 million to expand its operations and address its ambitious revenue goals. Overview of the Offering In a recent announcement, Duos unveiled that it will be offering 6,666,667 shares of its...

Continue Reading
Understanding TELUS Intl's Upcoming Earnings Report

Updated Category News Views 170

TELUS Intl Quarterly Earnings Overview TELUS Intl (TIXT) is preparing to unveil its quarterly earnings report, sparking interest among investors keen on understanding the company's performance and future outlook. As we approach the announcement, anticipation grows regarding the possible results and guidance. Investor Expectations Analysts have set their eyes on TELUS...

Continue Reading
America's Car-Mart Reports Q1 Results and Strategic Focus

Updated Category News Views 70

America's Car-Mart Focuses on Strategic Growth Amid Revenue Declines America's Car-Mart Inc. (NASDAQ: CRMT), a leading automotive retailer in the United States, has recently released its financial results for the first quarter of fiscal 2025. The company reported a revenue decline of 5.2%, primarily due to a decrease in retail units sold. However, America's Car-Mart is...

Continue Reading
Kayne Anderson Energy Infrastructure Fund Declares New Share Distribution

Updated Category News Views 108

Distribution Announcement from Kayne Anderson Energy Infrastructure Fund Kayne Anderson Energy Infrastructure Fund, Inc. has officially announced a monthly distribution of $0.08 per share. This upcoming payment is scheduled for common stockholders and highlights the fund's commitment to providing returns to its investors. Details of the Monthly Distribution The...

Continue Reading
Giftify, Inc. Celebrates Revenue Growth and Strategic Advancements

Updated Category News Views 249

Revenue Highlights and Profit Growth Giftify, Inc. (NASDAQ: GIFT), a major player in the incentives and rewards industry, reported impressive financial results for the first quarter. The company's revenue soared by 3.5%, reaching $22.3 million, demonstrating its resilience in a competitive market. Moreover, the company's gross profit increased by 10%, now standing at $3.6...

Continue Reading